Information Provided By:
Fly News Breaks for January 17, 2020
EOLS
Jan 17, 2020 | 10:19 EDT
Stifel analyst Annabel Samimy says that despite "positive news flow," shares of Evolus "remain depressed by overhangs." The analyst believes this presents a "strong buying opportunity" at current share levels. With all metrics "pointing in the right direction", Evolus has "strong tailwinds" continuing into 2020 and its sales momentum should continue, Samimy tells investors in a research note. With its singularity in focus on the toxin launch, Jeuveau is on target to be among the top five aesthetic product launches, reaching a number three position in less than six months, adds the analyst. Samimy maintains a Buy rating on Evolus with a $33 price target. The stock in morning trading is up 33c to $11.50.
News For EOLS From the Last 2 Days
EOLS
Apr 22, 2021 | 08:54 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - Renalytix... To see the rest of the story go to thefly.com. See Story Here
EOLS
Apr 21, 2021 | 18:51 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGSQualtrics... To see the rest of the story go to thefly.com. See Story Here
EOLS
Apr 21, 2021 | 16:02 EDT
SVB Leerink, Stifel and Cantor are acting as joint bookrunning managers for the offering.